Regeneron recently announced it would initiate a quarterly dividend of $0.88, a competitive amount for a company first ...

Eczema is an umbrella term for a group of conditions that result in skin irritation and inflammation. The most common form of ...

Lilly hopes that "patients see themselves reflected in the commercial," says Ashley Diaz-Granados, SVP of U.S. immunology ...

Dupixent is an eczema treatment whose rights Regeneron Pharmaceuticals ... comarkets with Bayer, treats wet age-related macular generation.

Regeneron's issues in the past year are almost entirely related to Eylea, a medicine for wet age-related macular ... However, the biotech can rely on Dupixent, an eczema treatment it co-markets ...

The article " Regeneron: Is It the Perfect Biotech Stock for Value and Growth? " first appeared on MarketBeat.

We recently published a list of the 11 Best Pharma Stocks to Buy According to Hedge Funds. In this article, we are going to ...

Clinical trial results found that a majority of patients with atopic dermatitis who were treated with Ebgylss achieved ...